MitoTEMPO hydrate

MitoTEMPO hydrate 是一种线粒体靶向抗氧化剂,可通过激活 PINK1/Parkin 通路诱导线粒体自噬 (autograpy)、抑制 NLRP3 炎症小体激活、恢复线粒体膜电位并改善肾功能和足细胞损伤,还可调控 Ca2+ 稳态、抑制 Bnip3 过表达、缩短动作电位时程以发挥抗心律失常作用,并可逆转早衰、减少小梁骨丢失、降低细胞凋亡 (apoptosis),可用于慢性肾脏病、年龄相关性心功能障碍、绝经后骨质疏松症和缺血性脑卒中的研究。
产品编号: MS-A73444 纯度: 98.03% CAS No.: 1569257-94-8 分子式: C29H37ClN2O3P 分子量: 528.04
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

MitoTEMPO hydrate 是一种线粒体靶向抗氧化剂,可通过激活 PINK1/Parkin 通路诱导线粒体自噬 (autograpy)、抑制 NLRP3 炎症小体激活、恢复线粒体膜电位并改善肾功能和足细胞损伤,还可调控 Ca2+ 稳态、抑制 Bnip3 过表达、缩短动作电位时程以发挥抗心律失常作用,并可逆转早衰、减少小梁骨丢失、降低细胞凋亡 (apoptosis),可用于慢性肾脏病、年龄相关性心功能障碍、绝经后骨质疏松症和缺血性脑卒中的研究。

生物实验数据

生物活性 MitoTEMPO hydrate is a mitochondria-targeted antioxidant that induces mitophagy (autograpy) by activating the PINK1/Parkin pathway, inhibits NLRP3 inflammasome activation, restores mitochondrial membrane potential, and ameliorates renal function and podocyte injury; it also regulates Ca2+ homeostasis, inhibits Bnip3 overexpression, and shortens action potential duration to exert antiarrhythmic effects, and it can reverse premature senescence, reduce trabecular bone loss, and decrease apoptosis (apoptosis), making it applicable for research on chronic kidney disease, age-related cardiac dysfunction, postmenopausal osteoporosis, and ischemic stroke.
体外研究
(In Vitro)

MitoTEMPO (200 μM; 24 h) hydrate 可抑制 NLRP3 炎症小体的活化,并保护人足细胞 (HPC) 免受 TNF-α 诱导的损伤。
MitoTEMPO (200 μM; 24 h) hydrate 可改善线粒体功能,并在 TNF-α 损伤的人足细胞 (HPC) 中诱导 PINK1/Parkin 通路介导的线粒体自噬。
MitoTEMPO (200 μM; 24 h) hydrate 以 Parkin 依赖的方式抑制经 TNF-α 损伤的人足细胞 (HPC) 中 NLRP3 炎症小体的激活。
MitoTEMPO (0.1-10 μM; 2 days) hydrate 可显著降低假手术组、短期去卵巢 (ST-OVX) 组和长期去卵巢 (LT-OVX) 组大鼠骨髓间充质干细胞 (BMSCs) 中的线粒体超氧化物水平,其中在 1 μM 浓度下对 LT-OVX 组 BMSCs 的作用最为显著。
MitoTEMPO (1 μM; 7 days) hydrate 可上调去卵巢长期模型 (LT-OVX) 大鼠骨髓间充质干细胞 (BMSCs) 中早期成骨标志物碱性磷酸酶 (ALP) 的活性,逆转雌激素缺乏引起的活性降低。
MitoTEMPO (1 μM; 2 days) hydrate 可通过降低衰老标志物表达、减少 DNA 损伤及改善细胞增殖障碍,缓解去卵巢 (LT-OVX) 大鼠骨髓间充质干细胞 (BMSCs) 的早衰现象。
MitoTEMPO (1 μM; 2 days) hydrate 可恢复溶酶体酸性并降低成熟 CTSB 水平,缓解雌激素缺乏诱导的去卵巢 (LT-OVX) 大鼠骨髓间充质干细胞 (BMSCs) 溶酶体功能障碍。
MitoTEMPO (1 μM; 2 days) hydrate 可增强去卵巢 (LT-OVX) 大鼠骨髓间充质干细胞 (BMSCs) 中的线粒体自噬,这一点可通过线粒体标志物与溶酶体标志物共定位水平的升高得到证实。
MitoTEMPO (1 μM; 2 days) hydrate 通过降低 HSP60 和 CLPP 蛋白表达,抑制雌激素缺乏诱导的去卵巢 (LT-OVX) 大鼠骨髓间充质干细胞 (BMSCs) 中线粒体未折叠蛋白反应 (UPRmt) 的激活。
MitoTEMPO (1 μM; 2 days) hydrate 可恢复去卵巢 (LT-OVX) 大鼠骨髓间充质干细胞 (BMSCs) 的线粒体膜电位,缓解雌激素缺乏诱导的线粒体功能障碍。
MitoTEMPO (1 μM; 2 days) hydrate 可改善去卵巢 (LT-OVX) 大鼠骨髓间充质干细胞 (BMSCs) 的线粒体呼吸功能,包括基础呼吸、ATP 偶联呼吸和最大呼吸。

Western Blot Analysis

Cell Line: human podocyte cells (HPC)
Concentration: 200 μM (Target Reagent); 100 nM (Parkin siRNA)
Incubation Time: 24 h (co-treated with TNF-α); 24 h (Parkin siRNA transfection prior to TNF-α and Target Reagent treatment)
Result: Lost the ability to significantly reduce the levels of NLRP3, cleaved caspase-1, or mature IL-1β in Parkin-silenced HPC, reversing the inhibitory effect observed in non-silenced cells.
体内研究
(In Vivo)

MitoTEMPO (0.7 mg/kg;腹腔注射;每日;连续 7 天) hydrate 可显著改善慢性肾脏病 (CKD) 模型大鼠的肾功能,减轻足细胞损伤,抑制 NLRP3 炎症小体激活,并诱导 PINK1/Parkin 通路介导的线粒体自噬。
MitoTEMPO (0.6 mg/kg;腹腔注射;每日 1 次;持续 4 周) hydrate 可缓解骨质疏松症去卵巢大鼠的骨小梁丢失,并降低衰老及线粒体应激标志物的表达。
MitoTEMPO (0.7 mg/kg/天;腹腔注射;每日给药;连续 14 天) hydrate 可对雄性 Wistar 白化大鼠的缺血再灌注诱导型心脏及神经功能障碍发挥保护作用,表现为与 IR 组相比,其血流动力学、心电图、生化及组织学指标均恢复正常。

Animal Model: Sprague-Dawley (male, 6-8 weeks old, 180-220 g, CKD induced by subcutaneous injection of 1 mg C-BSA emulsion followed by tail vein injection of 0.5 mg C-BSA every other day for 21 days)
Dosage: 0.7 mg/kg
Administration: i.p.; daily; 7 days
Result: Significantly reduced 24-hour urinary protein levels at 35 days post-modeling.
Decreased serum creatinine (SCR) and blood urea nitrogen (BUN) levels compared to CKD model rats.
Reduced mean density of podocyte injury marker desmin by ~55% compared to CKD model rats.
Increased mean density of slit diaphragm protein podocin compared to CKD model rats.
Suppressed podocyte foot process fusion and reduced thickened glomerular basement membrane (GBM) thickness compared to CKD model rats.
Reduced colocalization of NLRP3 and ASC in glomeruli compared to CKD model rats.
Decreased protein levels of NLRP3, cleaved caspase-1, and mature IL-1β compared to CKD model rats.
Lowered mRNA levels of IL-1β and TNF-α compared to CKD model rats.
Increased LC3 II/I ratio, PINK1, and Parkin protein levels compared to CKD model rats.
Decreased p62 protein levels compared to CKD model rats.
Enhanced colocalization of LC3 and mitochondrial marker COX IV compared to CKD model rats.
Animal Model: Sprague-Dawley (female, 10 weeks old at procurement, average weight 220 g; bilateral ovariectomy-induced osteoporosis model)
Dosage: 0.6 mg/kg
Administration: i.p.; daily; 4 weeks
Result: Significantly inhibited trabecular bone loss in OVX rats.
Improved trabecular bone thickness and density in treated OVX rats compared to vehicle-treated OVX rats.
Restored bone mineralization and deposition capabilities in treated OVX rats.
Reduced the expression of senescence-related marker p53 in the trabecular bone region of the proximal tibia.
Significantly decreased the expression of HSP60 and CLPP, markers of mitochondrial unfolded protein response, in OVX rats.
Animal Model: Wistar Albino (17-week-old male, initial body weight 250-304 g, middle cerebral artery occlusion followed by 3 days of reperfusion)
Dosage: 0.7 mg/kg/day
Administration: i.p.; daily; 14 days
Result: Increased final body weight to 302.57 g, compared to 285.75 g for the distilled water group.
Reduced heart weight/body weight ratio to 3.01 mg/g, which was statistically significantly lower than the ischemia-reperfusion (IR) group's 3.39 mg/g.
Normalized volume of electrically participating tissue, left ventricular ejection time, and heart rate to levels not significantly different from the sham group, and statistically significantly different from the IR group.
Normalized P-R interval, QTc, T-wave time, T-wave repolarization time, and R-R interval to levels not significantly different from the sham group, and statistically significantly different from the IR group.
Increased blood serum total antioxidant status (TAS) compared to the IR group; decreased total oxidant status (TOS) and oxidative stress index (OSI) compared to the IR group.
Increased heart left ventricle cyclic adenosine monophosphate (cAMP) and inositol triphosphate (IP3) levels to values close to the sham group and statistically significantly higher than the IR group.
Decreased brain right cerebral hemisphere catalase levels compared to the IR group.
Improved heart left ventricle tissue morphology to show mostly normal cardiac muscle cells with minimal myofibril degeneration, compared to widespread abnormalities in the IR group.
Improved brain right cerebral hemisphere tissue morphology to show mostly normal neurons and glial cells with fewer degenerative changes than the IR group.
性状 固体
颜色 Orange to red

化学信息

分子量 528.04
分子式 C29H37ClN2O3P
CAS No. 1569257-94-8

储存&溶解度

溶解度信息
DMSO: 5 mg/mL (9.47 mM), Sonication is recommmended.
PBS (pH 7.2): < 1 mg/mL (insoluble), Sonication is recommended.
Ethanol: 7.5 mg/mL (14.2 mM), Sonication is recommmended.
DMF: 7.5 mg/mL (14.2 mM), Sonication is recommmended.
储存方式

-20°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础